The results indicated that LMO1 and LMO2 genetic variants were associated with Wilms tumor susceptibility, which may help identify additional genetic susceptibility loci as novel biomarkers for the diagnosis and treatment of Wilms tumor. The gene discussed is LMO2; the disease is Nephroblastoma.